Skip to main content
. 2022 Jan 12;8:815628. doi: 10.3389/fmed.2021.815628

Table 2.

Comparison of the clinical features of 233 recurrence of ovarian endometrioma according to the presence of adenomyosis.

Subtype II (n = 112) Other types of adenomyosis (n = 55) Non-adenomyosis (n = 66) P- value
Postoperative GnRH therapy (n, %) 89 (79.46) 35 (63.64) 36 (54.55) 0.024
Postoperative LNG-IUD insertion (n, %) 24 (21.43) 8 (14.55) 6 (9.10) 0.032
3-year recurrence (n, %) 53/87 (60.92) 16/87(18.39) 18/87 (20.69) 0.028
5-year recurrence (n, %) 85/182 (46.70) 56/182 (30.77) 41/182 (22.53) 0.025
Time of OMA occurrence, mon 44.28 ± 8.37 63.96 ± 10.28 69.36 ± 9.34 0.017
Time of adenomyosis occurrence, mon 46.88 ± 12.20 69.76 ± 12.49 -
Time of pain recurrence, mon 47.12 ± 10.78 48.32 ± 12.08 48.73 ± 12.36 0.56
Pain symptom (n, %) 96 (85.71) 38 (69.10) 12 (18.18) 0.013
Duration of pain symptom, mon 28.88 ± 9.02 15.36 ± 7.85 5.67 ± 1.78 0.016
Duration of pain symptom >5 y (n, %) 21 (18.76) 7 (12.73) 6 (9.09) 0.67
Dysmenorrhea (n, %) 82 (73.21) 30 (54.55) 35 (53.03) 0.027
Dyspareunia (n, %) 47 (41.96) 24 (43.63) 25 (37.88) 0.58
Chronic pelvic pain (n, %) 27 (24.10) 13 (23.64) 15 (22.73) 0.86
VAS dysmenorrhea 7.81 ± 1.72 5.62 ± 1.61 4.45 ± 1.26 0.034
VAS dyspareunia 4.63 ± 2.81 4.65 ± 2.34 4.34 ± 1.84 0.72
VAS chronic pelvic pain 3.54 ± 2.76 3.64 ± 2.81 3.56 ± 2.17 0.78
Dysmenorrhea sever, VAS ≥ 7 (n, %) 53 (47.32) 26 (47.27) 31 (46.97) 0.69
Dyspareunia severe, VAS ≥ 7 (n, %) 32 (28.57) 17 (30.91) 16 (24.24) 0.83
No infertility (n, %) 65 (58.04) 43 (78.18) 55 (83.33) 0.035
Primary infertility (n, %) 35 (31.25) 8 (14.55) 7 (10.77) 0.014
Secondary infertility (n, %) 12 (10.71) 4 (7.27) 4 (6.06) 0.63
Duration of infertility >5 y (n, %) 17 (15.18) 3 (5.45) 2 (3.03) 0.015
Ca125 166.26 ± 28.86 171.2 ± 33.23 100.22 ± 27.64 0.65

Data are presented as means ± the standard deviation and n (%) as appropriate. Kruskal-Wallis followed by post-hoc Dunn's test or ANOVA test; χ2-test or Fisher's exact test; p < 0.05.